Fate Net Income from 2010 to 2026
| FATE Stock | USD 1.19 0.02 1.65% |
Net Loss | First Reported 2011-12-31 | Previous Quarter -34.1 M | Current Value -32.2 M | Quarterly Volatility 22.2 M |
Check Fate Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fate Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 22.9 M, Interest Expense of 7.1 M or Selling General Administrative of 89.6 M, as well as many indicators such as Price To Sales Ratio of 15.03, Dividend Yield of 0.0 or PTB Ratio of 0.5. Fate financial statements analysis is a perfect complement when working with Fate Therapeutics Valuation or Volatility modules.
Fate | Net Income | Build AI portfolio with Fate Stock |
Analyzing Fate Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Fate Therapeutics's current valuation and future prospects.
Latest Fate Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Fate Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Fate Therapeutics financial statement analysis. It represents the amount of money remaining after all of Fate Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Fate Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fate Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (186.26 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Fate Net Income Regression Statistics
| Arithmetic Mean | (98,452,754) | |
| Coefficient Of Variation | (83.84) | |
| Mean Deviation | 73,588,769 | |
| Median | (66,598,000) | |
| Standard Deviation | 82,538,621 | |
| Sample Variance | 6812.6T | |
| Range | 241.6M | |
| R-Value | (0.87) | |
| Mean Square Error | 1814.3T | |
| R-Squared | 0.75 | |
| Slope | (14,158,337) | |
| Total Sum of Squares | 109002T |
Fate Net Income History
Other Fundumenentals of Fate Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
About Fate Therapeutics Financial Statements
Fate Therapeutics stakeholders use historical fundamental indicators, such as Fate Therapeutics' Net Income, to determine how well the company is positioned to perform in the future. Although Fate Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Fate Therapeutics' assets and liabilities are reflected in the revenues and expenses on Fate Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Fate Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Check out the analysis of Fate Therapeutics Correlation against competitors. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Will Biotechnology sector continue expanding? Could Fate diversify its offerings? Factors like these will boost the valuation of Fate Therapeutics. Market participants price Fate higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fate Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.33) | Revenue Per Share | Quarterly Revenue Growth (0.43) | Return On Assets | Return On Equity |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fate Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.